ACADIA REPORTS POSITIVE RESULTS FROM TRIAL OF ACP-103

Acadia Pharmaceuticals has reported the results from a Phase II clinical trial of ACP-103 in patients with Parkinson's disease suffering from treatment-induced psychosis.

ACP-103 met the primary endpoint of the clinical trial -- motoric tolerability as measured by the Unified Parkinson's Disease Rating Scale -- by demonstrating that it did not worsen motor function in Parkinson's patients. The trial also evaluated secondary endpoints of antipsychotic efficacy using three different rating scales, and ACP-103 demonstrated antipsychotic effects on two of these rating scales. The drug was safe and well-tolerated in patients with Parkinson's disease.